

Study Title	A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation
Protocol Number	D1553-101
Sponsor	InventisBio Shanghai Limited
Contact	Li Hoon Lai, Oncology Research Team Leader at lihoonlai@cabrini.com.au

Study Type <i>Treatment</i>	Study Phase <i>Phase 1/2</i>	Recruitment Status <i>Open</i>	Lead Oncologist <i>A/Prof Gary Richardson</i>
---------------------------------------	--	--	---

Participation Eligibility

Participant eligibility for a trial may include age, gender, type and stage of disease, and previous or current treatments and health complications. Every trial has specific inclusion and exclusion criteria and these may differ from trial to trial. The inclusion and exclusion guidelines identify who can and cannot participate in this trial. A brief explanation of this study including the inclusion and exclusion criteria is available at this public domain website

<https://www.clinicaltrials.gov/ct2/show/NCT04585035?term=D1553-101&draw=2&rank=1>

If you need assistance understanding the eligibility criteria, you or your doctor can contact the study team